Wyeth's Effexor XR significantly relieves physical and emotional symptoms of depression and generalized anxiety disorder.

19 декабря, 2002
12/11/2002 Wyeth Pharmaceuticals announced that the serotonin-norepinephrine reuptake inhibitor antidepressant Effexor XR significantly relieved patients' physical and emotional symptoms related to depression and generalized anxiety disorder , according to data presented at an annual scientific meeting of neuropsychopharmacologists. Chemical Business NewsBase - Press Release via NewsEdge Corporation : 12/11/2002 Wyeth Pharmaceuticals announced that the serotonin-norepinephrine reuptake inhibitor antidepressant Effexor XR (venlafaxine HCl) significantly relieved patients' physical and emotional symptoms related to depression and generalized anxiety disorder (GAD), according to data presented at an annual scientific meeting of neuropsychopharmacologists. Effexor XR is believed to increase levels of both serotonin and norepinephrine, two of the brain chemicals thought to be implicated in depression and generalized anxiety disorders. Effexor XR was significantly effective in treating GAD patients' physical and emotional symptoms and equally effective regardless of the initial severity of physical symptoms, according to three pooled analyses of 1841 GAD patients in five double-blinded studies. Moreover, 767 GAD patients treated with Effexor XR and followed for six months demonstrated continued improvement across the spectrum of symptoms beyond their first eight weeks of therapy. Also, in depression patients, Effexor XR demonstrated greater therapeutic effect than selective serotonin reuptake inhibitors fluoxetine, paroxetine, and fluoxamine regardless of the severity of physical and emotional symptoms, according to two other pooled analyses of eight randomised, double-blind studies in 2045 patients. Patients with untreated or under-treated depression and GAD may suffer from an array of physical (somatic) and emotional (psychic) symptoms. Effexor XR was discovered and developed by Wyeth Pharmaceuticals, the pharmaceutical division of Wyeth. The product is also marketed by Wyeth Pharmaceuticals. The immediate-release formulation was approved by the FDA in 1993; the extended-release (XR) formulation was approved in 1997. These medications are available only by prescription. Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, cardiovascular disease, central nervous system, inflammation, haemophilia, oncology and vaccines. Copyright 2002. All Rights Reserved. Financial Times Information Limited - Asia Africa Intelligence Wire <> << Copyright ©2002 Financial Times Limited, All Rights Reserved >>
Разделы
Новости